Challenge your anti-CD38 expectations1
SARCLISA: The first and only FDA-approved anti-CD38 + VRd therapy in patients with NDMM not eligible for transplant1,2
Explore the IMROZ Trial
Review patient types for SARCLISA
Explore Patient Profiles
See the results for SARCLISA at first relapse
Explore RRMM
Isatuximab-irfc (SARCLISA) combination therapies: NCCN Category 1, Preferred regimens according to the National Comprehensive Cancer Network® (NCCN®)3
NCCN recommends isatuximab-irfc (SARCLISA) in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of:
NCCN
CATEGORY 1
PREFERRED
NEWLY DIAGNOSED MULTIPLE MYELOMA
In combination with bortezomib, lenalidomide, and dexamethasone:
- For the treatment of patients with newly diagnosed multiple myeloma who are non-transplant candidates (<80 years old who are not frail)
RELAPSED OR REFRACTORY MULTIPLE MYELOMA
In combination with carfilzomib and dexamethasone or with pomalidomide and dexamethasone:
- For early relapses (1-3 prior therapies)*
- Option for patients refractory to either lenalidomide or bortezomib
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Recommendation for isatuximab-irfc (SARCLISA) in combination with carfilzomib and dexamethasone based on results of interim analysis.
*After 2 prior therapies including lenalidomide and a proteasome inhibitor for isatuximab-irfc in combination with pomalidomide and dexamethasone.
FDA=Food and Drug Administration; NCCN=National Comprehensive Cancer Network® (NCCN®); NDMM=newly diagnosed multiple myeloma; RRMM=relapsed or refractory multiple myeloma; VRd=bortezomib, lenalidomide, dexamethasone.